French innovations win global recognition for water sustainability and research excellence
Kumulus SAS won the Innovative Projects Award (Small Projects category) for its patented atmospheric water generator, which extracts drinking water from air using a hybrid condensation and desiccant process. Designed to operate using solar energy, each machine produces around 30 litres of water per day. The machines were deployed in rural schools in Tunisia, ensuring clean water access for over 1,000 students and more than 100 staff members. The project helps reduce water-related illnesses and absenteeism.
'Being among the winners shows we can deliver the right technology to those who need it and help address water scarcity. I thank His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, not only for the award but for his leadership in prioritising sustainability and global water access across the Arab world,' said Iheb Triki, co-founder and CEO of Kumulus.
STEM SAS won the Innovative Research and Development Award (International Institutions category) for its AQUAHIVE solution, a next-generation membrane distillation system that purifies water using waste heat and minimal electricity. AQUAHIVE purifies seawater, brackish water and industrial wastewater through a patented low-temperature evaporation-condensation process. With a current technology readiness level of eight, the solution was showcased in the industrial environment of Dunkirk, France, earlier this year.
'When it comes to the global water crisis, the 3R rule – Reduce, Reuse, Recycle – is essential. Receiving this award made our entire team proud and renewed our motivation to reach new milestones. I sincerely thank His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, for championing innovation and sustainability. Leadership like his is vital to creating a better future,' said Frederic Walland, CEO of STEM SAS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Business Wire
an hour ago
- Business Wire
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
LEIDEN, Netherlands--(BUSINESS WIRE)-- Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros, and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' Share The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' said Stefano Portolano, Chief Executive Officer at Azafaros. 'We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy.' About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Forbes
2 hours ago
- Forbes
Mistral AI's Environmental Audit Puts Spotlight On AI's Hidden Costs
Mistral AI Mistral AI has quantified the environmental price of artificial intelligence with unprecedented transparency, releasing what appears to be the first comprehensive lifecycle assessment of a large language model. The French AI startup's detailed analysis of its Mistral Large 2 model reveals that training alone generated 20,400 metric tons of carbon dioxide equivalent and consumed 281,000 cubic meters of water over 18 months. This disclosure comes as enterprises face dual pressures - implementing AI to stay competitive while fulfilling sustainability commitments. The audit provides decision-makers with concrete data points that were previously hidden behind industry opacity, enabling more informed technology adoption strategies. The numbers from Mistral's assessment illustrate the resource intensity of AI. Training the 123 billion parameter model required energy equivalent to 4,500 gasoline-powered cars operating for a year, while water consumption matched filling 112 Olympic-sized swimming pools. Each individual query through Mistral's Le Chat assistant generates 1.14 grams of CO2 equivalent and consumes 45 milliliters of water, roughly equivalent to growing a small radish. Mistral AI More significantly, the analysis reveals that operational phases have a greater impact on the environment. Training and inference account for 85% of water consumption, far exceeding the environmental cost of hardware manufacturing or data center construction. This operational dominance means that environmental costs accumulate continuously as model usage scales up. Mistral's research identifies actionable strategies for reducing environmental impact. Geographic location has a significant influence on carbon footprint, with models trained in regions with renewable energy and cooler climates exhibiting markedly lower emissions. The study demonstrates a strong correlation between model size and environmental cost, with larger models generating impacts roughly one order of magnitude higher for equivalent token generation. These findings suggest specific optimization approaches. Enterprises can reduce environmental impact by selecting appropriately sized models for specific use cases rather than defaulting to larger, general-purpose systems. Continuous batching techniques that group queries can minimize computational waste, while deploying models in regions with clean energy grids substantially reduces carbon emissions. Mistral's disclosure strategy differs significantly from that of its competitors. While OpenAI CEO Sam Altman recently claimed ChatGPT queries consume just 0.32 milliliters of water per request, the lack of a detailed methodology makes meaningful comparison difficult. This transparency gap presents opportunities for companies willing to provide comprehensive environmental data, allowing them to differentiate themselves competitively. The audit establishes environmental transparency as a key differentiator in the enterprise AI market. As sustainability metrics increasingly influence procurement decisions, vendors providing detailed environmental impact data gain advantages in enterprise sales cycles. This transparency enables more sophisticated vendor evaluations that balance performance requirements against environmental costs. For technology executives, Mistral's audit provides decision-making criteria previously unavailable. Organizations can now factor environmental impact into AI procurement decisions, alongside traditional metrics such as performance and cost. The data enables more sophisticated total cost of ownership calculations that include environmental externalities. Looking ahead, environmental performance may become as critical as computational performance in selecting AI vendors. Organizations that establish environmental accounting practices now position themselves advantageously as regulatory requirements expand and stakeholder scrutiny intensifies. The Mistral audit demonstrates that detailed environmental measurement is feasible, potentially making opacity from other vendors increasingly untenable in enterprise markets.
